首页 > 最新文献

Clinical and Experimental Reproductive Medicine-CERM最新文献

英文 中文
The relationship between vitamin D levels and erectile dysfunction: A mini-review.
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-21 DOI: 10.5653/cerm.2024.07402
Aamir Javed, Sanaz A Movassagh, Shilpa Doultani, Tulsi Kumari, Rishish Sharma, Md Kashif Zeya, Syed Waseem Andrabi, Kamal Saba

The importance of maintaining adequate levels of vitamin D for optimal male sexual health is highlighted by recent evidence suggesting a link between vitamin D insufficiency and erectile dysfunction (ED). This review examines current research that indicates an association between decreased serum concentrations of 25-hydroxyvitamin D (25(OH)D), specifically levels below 20 ng/mL, and a higher prevalence of ED, including severe cases. Studies have shown a significant correlation between a decrease of 10 ng/mL in 25(OH)D levels and a 12% increase in the prevalence of ED. The active form of vitamin D, calcitriol, facilitates the synthesis of nitric oxide, a potent vasodilator crucial for penile erection. Additionally, vitamin D supplementation has been shown to improve erectile function by enhancing endothelial vasodilation and arterial blood flow. It is essential to maintain serum 25(OH)D levels within the recommended range of 20 to 50 ng/mL, given the connection between vascular disorders and ED. A comprehensive approach, including dietary changes, consistent physical activity, and lifestyle modifications, is necessary to prevent ED. While vitamin D deficiency may contribute to ED, it is crucial to recognize that ED is multifactorial and should be addressed by considering all underlying causes. Individuals consistently experiencing symptoms of ED are advised to consult healthcare professionals for appropriate therapeutic interventions. This review emphasizes the importance of considering serum vitamin D levels when assessing male sexual health and calls for further research to clarify the role of vitamin D in the etiology and treatment of ED.

最近有证据表明,维生素 D 不足与勃起功能障碍(ED)之间存在联系,这凸显了维持充足的维生素 D 水平对男性最佳性健康的重要性。本综述探讨了当前的研究,这些研究表明血清中 25- 羟基维生素 D(25(OH)D)浓度的降低,特别是低于 20 纳克/毫升的水平,与较高的 ED 患病率(包括严重病例)之间存在关联。研究表明,25(OH)D 水平每降低 10 纳克/毫升,ED 患病率就会增加 12%,两者之间存在明显的相关性。维生素 D 的活性形式--钙三醇能促进一氧化氮的合成,而一氧化氮是一种对阴茎勃起至关重要的强效血管扩张剂。此外,补充维生素 D 还能增强内皮血管扩张和动脉血流,从而改善勃起功能。鉴于血管疾病与 ED 之间的联系,将血清 25(OH)D 水平保持在 20 至 50 纳克/毫升的推荐范围内至关重要。预防 ED 需要采取综合措施,包括改变饮食习惯、坚持体育锻炼和改变生活方式。虽然维生素 D 缺乏可能是导致 ED 的原因之一,但必须认识到 ED 是由多种因素造成的,因此应通过考虑所有潜在原因来解决这一问题。建议持续出现 ED 症状的患者咨询医疗保健专业人员,以采取适当的治疗干预措施。本综述强调了在评估男性性健康时考虑血清维生素 D 水平的重要性,并呼吁开展进一步研究,以明确维生素 D 在 ED 病因学和治疗中的作用。
{"title":"The relationship between vitamin D levels and erectile dysfunction: A mini-review.","authors":"Aamir Javed, Sanaz A Movassagh, Shilpa Doultani, Tulsi Kumari, Rishish Sharma, Md Kashif Zeya, Syed Waseem Andrabi, Kamal Saba","doi":"10.5653/cerm.2024.07402","DOIUrl":"https://doi.org/10.5653/cerm.2024.07402","url":null,"abstract":"<p><p>The importance of maintaining adequate levels of vitamin D for optimal male sexual health is highlighted by recent evidence suggesting a link between vitamin D insufficiency and erectile dysfunction (ED). This review examines current research that indicates an association between decreased serum concentrations of 25-hydroxyvitamin D (25(OH)D), specifically levels below 20 ng/mL, and a higher prevalence of ED, including severe cases. Studies have shown a significant correlation between a decrease of 10 ng/mL in 25(OH)D levels and a 12% increase in the prevalence of ED. The active form of vitamin D, calcitriol, facilitates the synthesis of nitric oxide, a potent vasodilator crucial for penile erection. Additionally, vitamin D supplementation has been shown to improve erectile function by enhancing endothelial vasodilation and arterial blood flow. It is essential to maintain serum 25(OH)D levels within the recommended range of 20 to 50 ng/mL, given the connection between vascular disorders and ED. A comprehensive approach, including dietary changes, consistent physical activity, and lifestyle modifications, is necessary to prevent ED. While vitamin D deficiency may contribute to ED, it is crucial to recognize that ED is multifactorial and should be addressed by considering all underlying causes. Individuals consistently experiencing symptoms of ED are advised to consult healthcare professionals for appropriate therapeutic interventions. This review emphasizes the importance of considering serum vitamin D levels when assessing male sexual health and calls for further research to clarify the role of vitamin D in the etiology and treatment of ED.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent trends in polycystic ovary syndrome treatment based on adult stem cell therapies. 基于成体干细胞疗法的多囊卵巢综合症治疗的最新趋势。
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-21 DOI: 10.5653/cerm.2024.07248
Hyeri Park, Ji Woong Han, Gi Jin Kim

Adult stem cell therapy has emerged as a prominent area of interest in regenerative medicine, drawing attention from numerous researchers who are investigating its potential for treating degenerative diseases, especially those affecting the reproductive system. Despite the growing focus, critical elements such as the optimization of treatment parameters (e.g., transplantation [Tx] route, cell dosage) and enhancement of therapeutic efficacy are still areas of uncertainty. This review paper presents a thorough analysis of recent preclinical and clinical studies on adult stem cell therapy for ovarian dysfunction, specifically targeting conditions like polycystic ovary syndrome (PCOS). By examining these studies, the review seeks to clarify the current state of knowledge and pinpoint gaps in understanding, thereby establishing a robust foundation for future advancements in adult stem cell therapies aimed at ovarian dysfunction. Ultimately, this paper aims to offer valuable insights that could lead to improved treatment strategies in the field of reproductive system diseases.

{"title":"Recent trends in polycystic ovary syndrome treatment based on adult stem cell therapies.","authors":"Hyeri Park, Ji Woong Han, Gi Jin Kim","doi":"10.5653/cerm.2024.07248","DOIUrl":"https://doi.org/10.5653/cerm.2024.07248","url":null,"abstract":"<p><p>Adult stem cell therapy has emerged as a prominent area of interest in regenerative medicine, drawing attention from numerous researchers who are investigating its potential for treating degenerative diseases, especially those affecting the reproductive system. Despite the growing focus, critical elements such as the optimization of treatment parameters (e.g., transplantation [Tx] route, cell dosage) and enhancement of therapeutic efficacy are still areas of uncertainty. This review paper presents a thorough analysis of recent preclinical and clinical studies on adult stem cell therapy for ovarian dysfunction, specifically targeting conditions like polycystic ovary syndrome (PCOS). By examining these studies, the review seeks to clarify the current state of knowledge and pinpoint gaps in understanding, thereby establishing a robust foundation for future advancements in adult stem cell therapies aimed at ovarian dysfunction. Ultimately, this paper aims to offer valuable insights that could lead to improved treatment strategies in the field of reproductive system diseases.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters.
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-21 DOI: 10.5653/cerm.2024.07675
Young Jae Kim, Seoung Ryeol Lee, Young Dong Yu

Objective: To evaluate the long-term effects of dutasteride on male fertility and determine the cutoff treatment duration that causes significant and persistent decreases in semen parameters.

Methods: This was a single-center, randomized, controlled study that evaluated 200 men (ages 28 to 39 years). Forty men were allocated to each study group, divided according to the duration of dutasteride treatment, as follows: <6 months (group 1), 6-12 months (group 2), 13-18 months (group 3), 19-24 months (group 4), and >24 months (group 5). All subjects received dutasteride 0.5 mg/day for management of androgenetic alopecia then discontinued dutasteride for 6 months.

Results: The baseline mean testosterone level in the study subjects was 4.8 ng/mL. No significant differences were found between study groups in sperm concentration, normal morphology, and vitality. Semen volume and sperm total/progressive motility were significantly reduced as the duration of dutasteride treatment increased. All study groups showed an increase in total sperm motility and semen volume after discontinuation of dutasteride. Compared with group 1, groups 2-5 showed significant decreases in semen volume and sperm total motility, with the odds ratios becoming smaller as the duration of dutasteride treatment increased. Receiver operating characteristic analysis showed the cutoff values for persistent impairment of semen volume and total sperm motility to be 17.8 and 20.3 months, respectively.

Conclusion: Long-term use of dutasteride may lead to male infertility by persistently impairing semen volume and sperm motility.

{"title":"Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters.","authors":"Young Jae Kim, Seoung Ryeol Lee, Young Dong Yu","doi":"10.5653/cerm.2024.07675","DOIUrl":"https://doi.org/10.5653/cerm.2024.07675","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the long-term effects of dutasteride on male fertility and determine the cutoff treatment duration that causes significant and persistent decreases in semen parameters.</p><p><strong>Methods: </strong>This was a single-center, randomized, controlled study that evaluated 200 men (ages 28 to 39 years). Forty men were allocated to each study group, divided according to the duration of dutasteride treatment, as follows: <6 months (group 1), 6-12 months (group 2), 13-18 months (group 3), 19-24 months (group 4), and >24 months (group 5). All subjects received dutasteride 0.5 mg/day for management of androgenetic alopecia then discontinued dutasteride for 6 months.</p><p><strong>Results: </strong>The baseline mean testosterone level in the study subjects was 4.8 ng/mL. No significant differences were found between study groups in sperm concentration, normal morphology, and vitality. Semen volume and sperm total/progressive motility were significantly reduced as the duration of dutasteride treatment increased. All study groups showed an increase in total sperm motility and semen volume after discontinuation of dutasteride. Compared with group 1, groups 2-5 showed significant decreases in semen volume and sperm total motility, with the odds ratios becoming smaller as the duration of dutasteride treatment increased. Receiver operating characteristic analysis showed the cutoff values for persistent impairment of semen volume and total sperm motility to be 17.8 and 20.3 months, respectively.</p><p><strong>Conclusion: </strong>Long-term use of dutasteride may lead to male infertility by persistently impairing semen volume and sperm motility.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Various aspects of cryopreservation of small numbers of sperm in assisted reproductive technology.
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-21 DOI: 10.5653/cerm.2024.07241
Keivan Lorian, Azam Agha-Rahimi, Behnam Maleki

In cases of severe oligospermia and non-obstructive azoospermia, few spermatozoa with appropriate motility and viability are detected in epididymal and testicular samples. Sperm cryopreservation is performed to avoid multiple testis biopsies and to maintain samples. Consequently, various sperm retrieval methods are employed together with intracytoplasmic sperm injection. Common cryopreservation techniques are not ideal if there are few spermatozoa because sperm may be lost during the freezing and thawing procedures. Single sperm cryopreservation was first developed in 1997 and has since evolved in various aspects, including cryo-devices, freezing methods, cryoprotectants, and clinical and neonatal outcomes, as discussed in this comprehensive review. The CENTRAL, Embase, MEDLINE, PubMed, Scopus, and Web of Science databases were searched for relevant studies published during 1997-2023. Single sperm cryopreservation has been applied successfully for individuals with a limited number of spermatozoa. First, cryo-devices and their advantages and disadvantages are discussed. Furthermore, different aspects of this technique-including the use of testicular sperm rather than ejaculated sperm, proper cryoprotectants with ideal freezing outcomes, optimal cooling and warming rates, and testicular sperm selection prior to freezing-require more attention. This technique has been applied in clinical settings, and clinical outcomes have been reported using various carriers such as empty zonae pellucidae, straws, cell sleepers, cryotops, cryopieces, the sperm vitrification device (Sperm VD), and stripper tips. Furthermore, delivery rates have also been reported using this method. Nonetheless, more clinical trials are required to facilitate biological offspring through a practical platform.

{"title":"Various aspects of cryopreservation of small numbers of sperm in assisted reproductive technology.","authors":"Keivan Lorian, Azam Agha-Rahimi, Behnam Maleki","doi":"10.5653/cerm.2024.07241","DOIUrl":"https://doi.org/10.5653/cerm.2024.07241","url":null,"abstract":"<p><p>In cases of severe oligospermia and non-obstructive azoospermia, few spermatozoa with appropriate motility and viability are detected in epididymal and testicular samples. Sperm cryopreservation is performed to avoid multiple testis biopsies and to maintain samples. Consequently, various sperm retrieval methods are employed together with intracytoplasmic sperm injection. Common cryopreservation techniques are not ideal if there are few spermatozoa because sperm may be lost during the freezing and thawing procedures. Single sperm cryopreservation was first developed in 1997 and has since evolved in various aspects, including cryo-devices, freezing methods, cryoprotectants, and clinical and neonatal outcomes, as discussed in this comprehensive review. The CENTRAL, Embase, MEDLINE, PubMed, Scopus, and Web of Science databases were searched for relevant studies published during 1997-2023. Single sperm cryopreservation has been applied successfully for individuals with a limited number of spermatozoa. First, cryo-devices and their advantages and disadvantages are discussed. Furthermore, different aspects of this technique-including the use of testicular sperm rather than ejaculated sperm, proper cryoprotectants with ideal freezing outcomes, optimal cooling and warming rates, and testicular sperm selection prior to freezing-require more attention. This technique has been applied in clinical settings, and clinical outcomes have been reported using various carriers such as empty zonae pellucidae, straws, cell sleepers, cryotops, cryopieces, the sperm vitrification device (Sperm VD), and stripper tips. Furthermore, delivery rates have also been reported using this method. Nonetheless, more clinical trials are required to facilitate biological offspring through a practical platform.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical pregnancy rates after two different methods of laser-assisted hatching applied to vitrified-warmed day-3 embryos or day-5 blastocysts.
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-06 DOI: 10.5653/cerm.2024.07073
Woo Jeong Kim, Byung Chul Jee

Objective: Laser-assisted hatching (LAH) employs two distinct techniques: thinning and breaching. This study aimed to compare the clinical efficacy of combined thinning and breaching versus breaching alone in vitrified-warmed embryo or blastocyst transfer cycles.

Methods: In total, 110 vitrified-warmed day-3 embryo transfer cycles and 50 vitrified-warmed day-5 blastocyst transfer cycles were retrospectively selected. All transfers were performed between 2021 and 2022 at a university-based infertility center. Combined thinning and breaching involved thinning either one-quarter or one-sixth of the zona pellucida circumference combined with breaching at a single point.

Results: In vitrified-warmed day-3 embryo transfer cycles, the 'thinning and breaching' and 'breaching only' groups were similar regarding the median age of the woman (36 years vs. 37 years, respectively), number of embryos transferred (2 vs. 2), and embryo score (89 vs. 31.5). The clinical pregnancy rate (PR) (23.5% vs. 21.1%), embryo implantation rate (IR) (11.4% vs. 11.3%), and clinical miscarriage rate (25% vs. 37.5%) were also comparable between the two LAH groups. In vitrified-warmed day-5 blastocyst transfer cycles, the combination and breaching-only groups were similar in the median age of the woman (36 years vs. 36.5 years, respectively), number of blastocysts transferred (1 vs. 1), and blastocyst score (45 vs. 31.5). The clinical PR (45.5% vs. 42.9%), IR (35.4% vs. 33.3%), and clinical miscarriage rate (20% vs. 33.3%) were also similar between groups.

Conclusion: Breaching alone displayed similar efficacy to combined thinning and breaching in terms of clinical PR, IR, and miscarriage rate. Thus, breaching alone appears sufficient to achieve favorable pregnancy outcomes.

{"title":"Clinical pregnancy rates after two different methods of laser-assisted hatching applied to vitrified-warmed day-3 embryos or day-5 blastocysts.","authors":"Woo Jeong Kim, Byung Chul Jee","doi":"10.5653/cerm.2024.07073","DOIUrl":"https://doi.org/10.5653/cerm.2024.07073","url":null,"abstract":"<p><strong>Objective: </strong>Laser-assisted hatching (LAH) employs two distinct techniques: thinning and breaching. This study aimed to compare the clinical efficacy of combined thinning and breaching versus breaching alone in vitrified-warmed embryo or blastocyst transfer cycles.</p><p><strong>Methods: </strong>In total, 110 vitrified-warmed day-3 embryo transfer cycles and 50 vitrified-warmed day-5 blastocyst transfer cycles were retrospectively selected. All transfers were performed between 2021 and 2022 at a university-based infertility center. Combined thinning and breaching involved thinning either one-quarter or one-sixth of the zona pellucida circumference combined with breaching at a single point.</p><p><strong>Results: </strong>In vitrified-warmed day-3 embryo transfer cycles, the 'thinning and breaching' and 'breaching only' groups were similar regarding the median age of the woman (36 years vs. 37 years, respectively), number of embryos transferred (2 vs. 2), and embryo score (89 vs. 31.5). The clinical pregnancy rate (PR) (23.5% vs. 21.1%), embryo implantation rate (IR) (11.4% vs. 11.3%), and clinical miscarriage rate (25% vs. 37.5%) were also comparable between the two LAH groups. In vitrified-warmed day-5 blastocyst transfer cycles, the combination and breaching-only groups were similar in the median age of the woman (36 years vs. 36.5 years, respectively), number of blastocysts transferred (1 vs. 1), and blastocyst score (45 vs. 31.5). The clinical PR (45.5% vs. 42.9%), IR (35.4% vs. 33.3%), and clinical miscarriage rate (20% vs. 33.3%) were also similar between groups.</p><p><strong>Conclusion: </strong>Breaching alone displayed similar efficacy to combined thinning and breaching in terms of clinical PR, IR, and miscarriage rate. Thus, breaching alone appears sufficient to achieve favorable pregnancy outcomes.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of granulocyte-macrophage colony-stimulating factor in inducing autophagy in the spermatozoa of patients with asthenoteratozoospermia.
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-06 DOI: 10.5653/cerm.2024.07479
Tahereh Gheliji, Mohammad Hosain Haidari, Marefat Ghaffari Novin, Zahra Shams Mofarahe, Mahsa Kazemi, Latif Gachkar, Pourya Raee, Bahareh Karimi, Hamid Nazarian

Objective: The aim of this study is to investigate the effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment on the autophagy process and sperm parameters in individuals with asthenoteratozoospermia.

Methods: Twenty semen samples from patients diagnosed with asthenoteratozoospermia were divided into control and treatment groups. Subsequently, 2 ng/mL of GM-CSF was added to the treatment group samples. All samples were then incubated for 1 hour. Post-incubation, the protein levels of light chain 3 II (LC3-II)/LC3-I and autophagy related 7 (Atg7), which are well-known autophagy markers, along with sperm motility, viability, and sperm DNA fragmentation, were analyzed in both study groups.

Results: Our study demonstrated significant increases in LC3-II/LC3-I and Atg7 levels, as well as in sperm motility, in the GM-CSF group compared to the control group (p<0.0001). Furthermore, GM-CSF treatment significantly reduced necrotic cell death in the GM-CSF group relative to the control group (p<0.01). There were no significant differences between the groups in terms of sperm viability and DNA fragmentation (p>0.05).

Conclusion: These results revealed that GM-CSF has the potential to significantly induce autophagy in sperm and enhance sperm motility in patients with asthenoteratozoospermia, without adversely affecting sperm viability and DNA integrity. These findings suggest that modifying autophagy with physiological and safe components like GM-CSF may become a promising therapeutic strategy for treating male infertility in the near future.

{"title":"The role of granulocyte-macrophage colony-stimulating factor in inducing autophagy in the spermatozoa of patients with asthenoteratozoospermia.","authors":"Tahereh Gheliji, Mohammad Hosain Haidari, Marefat Ghaffari Novin, Zahra Shams Mofarahe, Mahsa Kazemi, Latif Gachkar, Pourya Raee, Bahareh Karimi, Hamid Nazarian","doi":"10.5653/cerm.2024.07479","DOIUrl":"https://doi.org/10.5653/cerm.2024.07479","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to investigate the effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment on the autophagy process and sperm parameters in individuals with asthenoteratozoospermia.</p><p><strong>Methods: </strong>Twenty semen samples from patients diagnosed with asthenoteratozoospermia were divided into control and treatment groups. Subsequently, 2 ng/mL of GM-CSF was added to the treatment group samples. All samples were then incubated for 1 hour. Post-incubation, the protein levels of light chain 3 II (LC3-II)/LC3-I and autophagy related 7 (Atg7), which are well-known autophagy markers, along with sperm motility, viability, and sperm DNA fragmentation, were analyzed in both study groups.</p><p><strong>Results: </strong>Our study demonstrated significant increases in LC3-II/LC3-I and Atg7 levels, as well as in sperm motility, in the GM-CSF group compared to the control group (p<0.0001). Furthermore, GM-CSF treatment significantly reduced necrotic cell death in the GM-CSF group relative to the control group (p<0.01). There were no significant differences between the groups in terms of sperm viability and DNA fragmentation (p>0.05).</p><p><strong>Conclusion: </strong>These results revealed that GM-CSF has the potential to significantly induce autophagy in sperm and enhance sperm motility in patients with asthenoteratozoospermia, without adversely affecting sperm viability and DNA integrity. These findings suggest that modifying autophagy with physiological and safe components like GM-CSF may become a promising therapeutic strategy for treating male infertility in the near future.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between thyroid-stimulating hormone levels and the severity of vitamin D deficiency by age group. 各年龄组促甲状腺激素水平与维生素 D 缺乏症严重程度之间的关系。
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-01 Epub Date: 2024-08-19 DOI: 10.5653/cerm.2023.06779
Mansi Modi, Pinky Garg

Objective: Researchers have long been captivated by the complex molecular interactions between vitamin D and the thyroid gland. Hypothyroidism affects 2% to 4% of women of reproductive age and can impact fertility through anovulatory cycles, luteal phase defects, hyperprolactinemia, and sex hormone imbalances. This study investigated the relationship between thyroid disease and the severity of vitamin D deficiency across different age groups.

Methods: A retrospective study was conducted of 286 patient samples from individuals aged 18 to 60 years who were processed in the clinical biochemistry laboratory of our hospital. Samples were tested for thyroid-stimulating hormone (TSH) and vitamin D (specifically, vitamin D3) levels. The study samples were categorized into four clinically relevant groups based on TSH levels and into three groups based on serum 25-hydroxyvitamin D (25(OH)D) levels.

Results: Most of the samples were from female patients (n=269), and the most common age group was 18 to 35 years (n=191, 66.78%). Subclinical hypothyroidism was identified in 120 patients, while vitamin D deficiency was present in 237 (82.87%) participants. A significant association was observed between vitamin D deficiency and the presence of thyroid disorders. Additionally, a significant negative correlation was found between TSH and vitamin D levels. Polycystic ovary syndrome was noted in 103 female patients (36.01%).

Conclusion: TSH and 25(OH)D levels should be screened in all women of reproductive age, not just those in high-risk groups, as subclinical and occult hypothyroidism may otherwise go undiagnosed. Furthermore, TSH should be considered the primary screening test.

研究目的长期以来,研究人员一直被维生素 D 与甲状腺之间复杂的分子相互作用所吸引。甲状腺功能减退症影响着2%至4%的育龄妇女,可通过无排卵周期、黄体期缺陷、高催乳素血症和性激素失衡影响生育能力。本研究调查了甲状腺疾病与不同年龄组维生素 D 缺乏严重程度之间的关系:我们对本院临床生化实验室处理的286份患者样本进行了回顾性研究,这些样本来自18至60岁的人群。对样本进行了促甲状腺激素(TSH)和维生素 D(特别是维生素 D3)水平检测。研究样本根据促甲状腺激素水平分为四个临床相关组,根据血清 25- 羟维生素 D(25(OH)D)水平分为三组:大多数样本来自女性患者(269 人),最常见的年龄组为 18 至 35 岁(191 人,66.78%)。在 120 名患者中发现了亚临床甲状腺功能减退症,而在 237 名参与者(82.87%)中发现了维生素 D 缺乏症。观察发现,维生素 D 缺乏与甲状腺疾病之间存在明显关联。此外,还发现促甲状腺激素和维生素 D 水平之间存在明显的负相关。103名女性患者(36.01%)患有多囊卵巢综合征:结论:所有育龄妇女都应接受促甲状腺激素和25(OH)D水平的筛查,而不仅仅是那些高危人群,因为亚临床和隐匿性甲状腺功能减退症可能会被漏诊。此外,促甲状腺激素应被视为主要的筛查项目。
{"title":"Relationship between thyroid-stimulating hormone levels and the severity of vitamin D deficiency by age group.","authors":"Mansi Modi, Pinky Garg","doi":"10.5653/cerm.2023.06779","DOIUrl":"10.5653/cerm.2023.06779","url":null,"abstract":"<p><strong>Objective: </strong>Researchers have long been captivated by the complex molecular interactions between vitamin D and the thyroid gland. Hypothyroidism affects 2% to 4% of women of reproductive age and can impact fertility through anovulatory cycles, luteal phase defects, hyperprolactinemia, and sex hormone imbalances. This study investigated the relationship between thyroid disease and the severity of vitamin D deficiency across different age groups.</p><p><strong>Methods: </strong>A retrospective study was conducted of 286 patient samples from individuals aged 18 to 60 years who were processed in the clinical biochemistry laboratory of our hospital. Samples were tested for thyroid-stimulating hormone (TSH) and vitamin D (specifically, vitamin D3) levels. The study samples were categorized into four clinically relevant groups based on TSH levels and into three groups based on serum 25-hydroxyvitamin D (25(OH)D) levels.</p><p><strong>Results: </strong>Most of the samples were from female patients (n=269), and the most common age group was 18 to 35 years (n=191, 66.78%). Subclinical hypothyroidism was identified in 120 patients, while vitamin D deficiency was present in 237 (82.87%) participants. A significant association was observed between vitamin D deficiency and the presence of thyroid disorders. Additionally, a significant negative correlation was found between TSH and vitamin D levels. Polycystic ovary syndrome was noted in 103 female patients (36.01%).</p><p><strong>Conclusion: </strong>TSH and 25(OH)D levels should be screened in all women of reproductive age, not just those in high-risk groups, as subclinical and occult hypothyroidism may otherwise go undiagnosed. Furthermore, TSH should be considered the primary screening test.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"71-78"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11900663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of dietary inflammatory indices (DII and E-DII) with sperm parameters. 膳食炎症指数(DII 和 E-DII)与精子参数的关系。
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-01 Epub Date: 2024-08-01 DOI: 10.5653/cerm.2024.06982
Sonia Sadeghpour, Fatemeh Maleki Sedgi, Sevana Daneghian, Somayyeh Barania Adabi, Tahereh Behroozi-Lak, Mohammadreza Pashaei, Javad RasouIi, Rohollah Valizadeh, Hojat Ghasemnejad-Berenji

Objective: This study aimed to explore the ambiguous link between dietary inflammatory indices and sperm parameters. Specifically, it investigated the associations between the dietary inflammatory index (DII) and the energy-adjusted dietary inflammatory index (E-DII) with sperm motility, morphology, and count in men undergoing routine semen analysis.

Methods: A cross-sectional study was conducted with 144 men enrolled, where semen samples were collected and evaluated according to the 2010 World Health Organization guidelines. Dietary data were gathered using a 147-item semi-quantitative food frequency questionnaire developed by the researchers. Pearson correlation analysis was employed to assess the relationships of the DII and E-DII with sperm parameters.

Results: The mean DII and E-DII scores were 1.23±1.1 and 0.49±0.43, respectively. The mean values for sperm motility, morphology, and count were 43.08%±19.30%, 78.03%±26.99%, and 48.12±44.41 million, respectively. Both motility (r=-0.353) and count (r=-0.348) were found to be inversely and significantly correlated with DII. Similarly, Pearson correlation tests revealed strong and significant inverse correlations of motility (r=-0.389) and count (r=-0.372) with E-DII.

Conclusion: The findings suggest that a diet with a higher anti-inflammatory potential may be associated with increased sperm count and motility, but not with changes in morphology. Further research is necessary to confirm these findings, elucidate the underlying mechanisms, and identify dietary modifications that could improve male fertility.

研究目的本研究旨在探讨膳食炎症指数与精子参数之间的模糊联系。具体来说,它调查了接受常规精液分析的男性的膳食炎症指数(DII)和能量调整膳食炎症指数(E-DII)与精子活力、形态和数量之间的关系:这项横断面研究共有 144 名男性参加,根据 2010 年世界卫生组织指南收集和评估精液样本。研究人员使用自己编制的 147 项半定量食物频率问卷收集了饮食数据。采用皮尔逊相关分析评估 DII 和 E-DII 与精子参数的关系:结果:DII和E-DII的平均值分别为1.23±1.1和0.49±0.43。精子活力、形态和数量的平均值分别为 43.08%±19.30%、78.03%±26.99% 和 48.12±44.41 百万。研究发现,精子活力(r=-0.353)和精子数量(r=-0.348)与精子活力指数呈显著的反相关。同样,Pearson 相关性检验也显示,蠕动(r=-0.389)和计数(r=-0.372)与 E-DII 呈显著的反向相关:研究结果表明,抗炎潜力较高的饮食可能与精子数量和活力的增加有关,但与形态的变化无关。有必要开展进一步研究,以证实这些发现,阐明其潜在机制,并确定可提高男性生育能力的饮食调整方法。
{"title":"Associations of dietary inflammatory indices (DII and E-DII) with sperm parameters.","authors":"Sonia Sadeghpour, Fatemeh Maleki Sedgi, Sevana Daneghian, Somayyeh Barania Adabi, Tahereh Behroozi-Lak, Mohammadreza Pashaei, Javad RasouIi, Rohollah Valizadeh, Hojat Ghasemnejad-Berenji","doi":"10.5653/cerm.2024.06982","DOIUrl":"10.5653/cerm.2024.06982","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the ambiguous link between dietary inflammatory indices and sperm parameters. Specifically, it investigated the associations between the dietary inflammatory index (DII) and the energy-adjusted dietary inflammatory index (E-DII) with sperm motility, morphology, and count in men undergoing routine semen analysis.</p><p><strong>Methods: </strong>A cross-sectional study was conducted with 144 men enrolled, where semen samples were collected and evaluated according to the 2010 World Health Organization guidelines. Dietary data were gathered using a 147-item semi-quantitative food frequency questionnaire developed by the researchers. Pearson correlation analysis was employed to assess the relationships of the DII and E-DII with sperm parameters.</p><p><strong>Results: </strong>The mean DII and E-DII scores were 1.23±1.1 and 0.49±0.43, respectively. The mean values for sperm motility, morphology, and count were 43.08%±19.30%, 78.03%±26.99%, and 48.12±44.41 million, respectively. Both motility (r=-0.353) and count (r=-0.348) were found to be inversely and significantly correlated with DII. Similarly, Pearson correlation tests revealed strong and significant inverse correlations of motility (r=-0.389) and count (r=-0.372) with E-DII.</p><p><strong>Conclusion: </strong>The findings suggest that a diet with a higher anti-inflammatory potential may be associated with increased sperm count and motility, but not with changes in morphology. Further research is necessary to confirm these findings, elucidate the underlying mechanisms, and identify dietary modifications that could improve male fertility.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":" ","pages":"79-86"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11900668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of anxiety, depression, and sexual dysfunction in women undergoing fertility treatment.
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-01 Epub Date: 2025-02-28 DOI: 10.5653/cerm.2024.07465
Joon Cheol Park

Objective: Infertility and fertility treatment can lead to considerable physical, emotional, and psychological distress. These effects may be influenced by personality, familial bonds, and support systems within a sociocultural context. This preliminary investigation examined anxiety, depression, and sexual dysfunction in Korean women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).

Methods: Women scheduled for IVF/ICSI and healthy women seeking general health screening (controls) were enrolled. Participants were asked to complete standardized, validated questionnaires-the Hospital Anxiety and Depression Scale (HADS), Depression Anxiety and Stress Scale (DASS), and Female Sexual Function Index (FSFI)-to assess their levels of anxiety, depression, and sexual function.

Results: The mean HADS scores for women undergoing IVF/ICSI were 6.35±3.48 (range, 0 to 13) for anxiety and 8.32±3.78 (range, 2 to 15) for depression. However, 12.9% of the women with infertility experienced clinically significant anxiety (HADS-Anxiety score >11), while 32.3% exhibited depression (HADS-Depression score >11). Based on DASS scores, psychological difficulties were more prevalent among women experiencing infertility than among control participants. Total FSFI scores, along with subscale ratings for desire, arousal, lubrication, satisfaction, and pain, were similar between women with infertility and control women. However, the mean score for orgasm was significantly lower in the infertility group (3.16) than among controls. Age, the durations of marriage and infertility, and parity did not significantly influence HADS, DASS, or FSFI scores.

Conclusion: Anxiety and depression were more prevalent among women seeking fertility treatment than among healthy controls. Additionally, women with infertility may experience fewer or diminished orgasms.

{"title":"Assessment of anxiety, depression, and sexual dysfunction in women undergoing fertility treatment.","authors":"Joon Cheol Park","doi":"10.5653/cerm.2024.07465","DOIUrl":"10.5653/cerm.2024.07465","url":null,"abstract":"<p><strong>Objective: </strong>Infertility and fertility treatment can lead to considerable physical, emotional, and psychological distress. These effects may be influenced by personality, familial bonds, and support systems within a sociocultural context. This preliminary investigation examined anxiety, depression, and sexual dysfunction in Korean women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).</p><p><strong>Methods: </strong>Women scheduled for IVF/ICSI and healthy women seeking general health screening (controls) were enrolled. Participants were asked to complete standardized, validated questionnaires-the Hospital Anxiety and Depression Scale (HADS), Depression Anxiety and Stress Scale (DASS), and Female Sexual Function Index (FSFI)-to assess their levels of anxiety, depression, and sexual function.</p><p><strong>Results: </strong>The mean HADS scores for women undergoing IVF/ICSI were 6.35±3.48 (range, 0 to 13) for anxiety and 8.32±3.78 (range, 2 to 15) for depression. However, 12.9% of the women with infertility experienced clinically significant anxiety (HADS-Anxiety score >11), while 32.3% exhibited depression (HADS-Depression score >11). Based on DASS scores, psychological difficulties were more prevalent among women experiencing infertility than among control participants. Total FSFI scores, along with subscale ratings for desire, arousal, lubrication, satisfaction, and pain, were similar between women with infertility and control women. However, the mean score for orgasm was significantly lower in the infertility group (3.16) than among controls. Age, the durations of marriage and infertility, and parity did not significantly influence HADS, DASS, or FSFI scores.</p><p><strong>Conclusion: </strong>Anxiety and depression were more prevalent among women seeking fertility treatment than among healthy controls. Additionally, women with infertility may experience fewer or diminished orgasms.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":"52 1","pages":"38-43"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11900670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum miR-329-3p as a potential biomarker for poor ovarian response in an in vitro fertilization.
IF 1.8 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-03-01 Epub Date: 2025-01-21 DOI: 10.5653/cerm.2024.07094
Jung Hoon Kim, Hye-Ok Kim, Su-Yeon Lee, Eun-A Park, Kyoung Hee Choi, Kiye Kang, Eun Jeong Yu, Mi Kyoung Koong, Kyung-Ah Lee

Objective: Several miRNAs have been identified as differentially expressed in patients with poor ovarian response (POR) compared to those with normal responses. This study aims to assess the potential of serum miR-329-3p as a biomarker for diagnosing POR.

Methods: We conducted a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to confirm the target genes of miR-329-3p. KGN cells were transfected with both miR-329-3p mimic and inhibitor to assess the differential expression of these target genes. In accordance with the Bologna criteria, we enrolled 16 control patients and 16 patients with POR. We collected patient samples, including serum from day 2 and the human chorionic gonadotropin (hCG) day, as well as granulosa and cumulus cells, to validate the expression of miR-329-3p using quantitative real-time polymerase chain reaction.

Results: KEGG pathway analysis revealed that miR-329-3p targeted adenylyl cyclase 9 (ADCY9) and protein kinase A subunit beta (PRKACB), both of which are involved in ovarian steroidogenesis. In KGN cells treated with a miR-329-3p mimic, ADCY9 and PRKACB expression levels were significantly reduced (p<0.05). Elevated levels of miR-329-3p suppressed aromatase expression and 17β-estradiol production by modulating ADCY9 and PRKACB in KGN cells. These effects were also observed in POR patients. Follicle-stimulating hormone receptor (FSHR) expression was diminished in the granulosa cells of POR patients. On day 2, on hCG day, and in granulosa cells, miR-329-3p exhibited high expression levels in the serum of POR patients.

Conclusion: miR-329-3p exhibited increased expression in granulosa cells and in the sera of POR patients. Consequently, we propose that miR-329-3p may be a potential biomarker for the diagnosis of POR.

{"title":"Serum miR-329-3p as a potential biomarker for poor ovarian response in an in vitro fertilization.","authors":"Jung Hoon Kim, Hye-Ok Kim, Su-Yeon Lee, Eun-A Park, Kyoung Hee Choi, Kiye Kang, Eun Jeong Yu, Mi Kyoung Koong, Kyung-Ah Lee","doi":"10.5653/cerm.2024.07094","DOIUrl":"10.5653/cerm.2024.07094","url":null,"abstract":"<p><strong>Objective: </strong>Several miRNAs have been identified as differentially expressed in patients with poor ovarian response (POR) compared to those with normal responses. This study aims to assess the potential of serum miR-329-3p as a biomarker for diagnosing POR.</p><p><strong>Methods: </strong>We conducted a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to confirm the target genes of miR-329-3p. KGN cells were transfected with both miR-329-3p mimic and inhibitor to assess the differential expression of these target genes. In accordance with the Bologna criteria, we enrolled 16 control patients and 16 patients with POR. We collected patient samples, including serum from day 2 and the human chorionic gonadotropin (hCG) day, as well as granulosa and cumulus cells, to validate the expression of miR-329-3p using quantitative real-time polymerase chain reaction.</p><p><strong>Results: </strong>KEGG pathway analysis revealed that miR-329-3p targeted adenylyl cyclase 9 (ADCY9) and protein kinase A subunit beta (PRKACB), both of which are involved in ovarian steroidogenesis. In KGN cells treated with a miR-329-3p mimic, ADCY9 and PRKACB expression levels were significantly reduced (p<0.05). Elevated levels of miR-329-3p suppressed aromatase expression and 17β-estradiol production by modulating ADCY9 and PRKACB in KGN cells. These effects were also observed in POR patients. Follicle-stimulating hormone receptor (FSHR) expression was diminished in the granulosa cells of POR patients. On day 2, on hCG day, and in granulosa cells, miR-329-3p exhibited high expression levels in the serum of POR patients.</p><p><strong>Conclusion: </strong>miR-329-3p exhibited increased expression in granulosa cells and in the sera of POR patients. Consequently, we propose that miR-329-3p may be a potential biomarker for the diagnosis of POR.</p>","PeriodicalId":46409,"journal":{"name":"Clinical and Experimental Reproductive Medicine-CERM","volume":"52 1","pages":"44-55"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11900665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Experimental Reproductive Medicine-CERM
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1